Core EBITDA and Margin Improvement
Core EBITDA reached EUR 66.2 million in 2025, a 31% increase versus 2024, with a core EBITDA margin of 7.8% (up from 5.5%). Reported EBITDA moved to ~EUR 10 million versus negative EUR 44 million in 2024.
Strong Cash Generation and Net Cash Position
Operating cash flow generated EUR 128.5 million in 2025. Free cash flow before financing was EUR 51.5 million (vs EUR 15.0 million in 2024). Net cash position improved to EUR 68.2 million at year-end 2025 from EUR 24.6 million at end-2024.
Working Capital Improvements
Working capital contributed EUR 120.1 million to cash flow, including inventory reduction of EUR 38.9 million and trade receivables reduction of EUR 45.4 million (of which EUR 26.5 million was factored). Months on hand stood at 7 and DSO at 36.
Sustained Cost Discipline and OpEx Savings
The company sustainably reduced external expenses and personnel costs; ~EUR 20 million of OpEx savings delivered over the past two years and 380 positions removed as part of footprint/organization simplification.
CapEx Discipline with Targeted Strategic Investment
CapEx was EUR 77 million in 2025 (≈9% of net sales), down from EUR 108 million in 2024 and EUR 137 million in 2023. 65% of 2025 CapEx was dedicated to growth/performance projects (peptides, oligonucleotides, prostaglandins, corticosteroids).
Sustainability Milestones Achieved
Near-term carbon emission reduction targets were validated by SBTi; company achieved half of its targeted Scope 1 & 2 reductions in 2025 and exceeded its Scope 3 target.
Portfolio Quality and FOCUS-27 Progress
66% of 2025 sales came from differentiated products (up from 57% at end-2023) and the company is on track toward a 70% target by 2027. CDMO pipeline quality improved with ~70% of projects late-stage; Haverhill divested and industrial consolidation actions executed.
Improved Financial Expenses and Financing
Net financial expenses improved by EUR 7.5 million versus 2024 and reported cost of debt decreased to around EUR 3 million following refinancing and financing plan implementation.